NTRA
Natera Inc
NASDAQ: NTRA · HEALTHCARE · DIAGNOSTICS & RESEARCH
$328.93
+0.86% today
Updated 2026-09-11
Market cap
$46.72B
P/E ratio
—
P/S ratio
17.26x
EPS (TTM)
$-1.36
Dividend yield
—
52W range
$157 – $343
Volume
1.2M
Natera Inc (NTRA) Insider transactions
Net insider activity
Net selling (133,456 shares)
Buy transactions
15
Sell transactions
85
All transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2029-06-23 | BROPHY, MICHAEL BURKES | Chief Financial Officer | Sale | 12,500 | — | — |
| 2029-06-08 | BROPHY, MICHAEL BURKES | Chief Financial Officer | Sale | 25,000 | — | — |
| 2026-09-02 | MOSHKEVICH, SOLOMON | PRESIDENT, CLINICALDIAGNOSTICS | Sale | 15,160 | $326.89 | $4.96M |
| 2026-09-01 | MOSHKEVICH, SOLOMON | PRESIDENT, CLINICALDIAGNOSTICS | Sale | 1,400 | $320.92 | $449291.50 |
| 2026-09-01 | MOSHKEVICH, SOLOMON | PRESIDENT, CLINICALDIAGNOSTICS | Sale | 1,000 | $319.76 | $319758.20 |
| 2026-09-01 | MOSHKEVICH, SOLOMON | PRESIDENT, CLINICALDIAGNOSTICS | Sale | 600 | $321.91 | $193144.02 |
| 2026-09-01 | CHAPMAN, STEVEN LEONARD | Director, CEO AND PRESIDENT | Sale | 1,698 | $320.99 | $545041.02 |
| 2026-08-10 | SHEENA, JONATHAN | Director, CO-FOUNDER | Sale | 6,000 | $325.32 | $1.95M |
| 2026-08-10 | FESKO, JOHN | PRESIDENT, CHIEF BUS. OFFICER | Sale | 6,517 | $321.53 | $2.10M |
| 2026-08-07 | SHEENA, JONATHAN | Director, CO-FOUNDER | Sale | 5,111 | $316.61 | $1.62M |
| 2026-08-07 | SHEENA, JONATHAN | Director, CO-FOUNDER | Sale | 900 | $313.07 | $281760.48 |
| 2026-08-07 | SHEENA, JONATHAN | Director, CO-FOUNDER | Sale | 850 | $314.25 | $267113.95 |
| 2026-08-07 | SHEENA, JONATHAN | Director, CO-FOUNDER | Sale | 600 | $315.32 | $189190.50 |
| 2026-08-07 | SHEENA, JONATHAN | Director, CO-FOUNDER | Sale | 489 | $320.90 | $156920.10 |
| 2026-08-07 | SHEENA, JONATHAN | Director, CO-FOUNDER | Sale | 400 | $310.23 | $124090.00 |
| 2026-08-07 | SHEENA, JONATHAN | Director, CO-FOUNDER | Sale | 200 | $317.97 | $63593.00 |
| 2026-08-07 | SHEENA, JONATHAN | Director, CO-FOUNDER | Sale | 100 | $318.63 | $31863.00 |
| 2026-08-07 | RABINOWITZ, MATTHEW | Director, EXECUTIVE CHAIRMAN | Sale | 2,000 | $320.90 | $641800.00 |
| 2026-08-06 | FESKO, JOHN | PRESIDENT, CHIEF BUS. OFFICER | Buy | 20,000 | — | — |
| 2026-08-04 | BROPHY, MICHAEL BURKES | CHIEF FINANCIAL OFFICER | Sale | 478 | $274.22 | $131077.16 |
| 2026-08-03 | SHEENA, JONATHAN | Director, CO-FOUNDER | Sale | 109 | $267.99 | $29210.83 |
| 2026-08-03 | RABINOWITZ, MATTHEW | Director, EXECUTIVE CHAIRMAN | Sale | 731 | $267.99 | $195900.18 |
| 2026-08-03 | RABINOWITZ, DANIEL | SEC. AND CHIEF LEGAL OFFICER | Sale | 334 | $267.99 | $89508.43 |
| 2026-08-03 | MOSHKEVICH, SOLOMON | PRESIDENT, CLINICALDIAGNOSTICS | Sale | 1,233 | $267.79 | $330181.25 |
| 2026-08-03 | MOSHKEVICH, SOLOMON | PRESIDENT, CLINICALDIAGNOSTICS | Sale | 947 | $263.94 | $249952.60 |
| 2026-08-03 | MOSHKEVICH, SOLOMON | PRESIDENT, CLINICALDIAGNOSTICS | Sale | 410 | $267.99 | $109875.61 |
| 2026-08-03 | MOSHKEVICH, SOLOMON | PRESIDENT, CLINICALDIAGNOSTICS | Sale | 300 | $259.98 | $77994.00 |
| 2026-08-03 | MOSHKEVICH, SOLOMON | PRESIDENT, CLINICALDIAGNOSTICS | Sale | 200 | $261.49 | $52297.50 |
| 2026-08-03 | MOSHKEVICH, SOLOMON | PRESIDENT, CLINICALDIAGNOSTICS | Sale | 192 | $265.28 | $50932.80 |
| 2026-08-03 | MOSHKEVICH, SOLOMON | PRESIDENT, CLINICALDIAGNOSTICS | Sale | 128 | $268.70 | $34393.14 |
| 2026-08-03 | FESKO, JOHN | PRESIDENT, CHIEF BUS. OFFICER | Sale | 295 | $267.99 | $79056.84 |
| 2026-08-03 | CHAPMAN, STEVEN LEONARD | Director, CEO AND PRESIDENT | Sale | 1,182 | $267.99 | $316763.35 |
| 2026-08-03 | CHAPMAN, STEVEN LEONARD | Director, CEO AND PRESIDENT | Sale | 676 | $263.86 | $178370.85 |
| 2026-08-03 | CHAPMAN, STEVEN LEONARD | Director, CEO AND PRESIDENT | Sale | 612 | $268.22 | $164149.84 |
| 2026-08-03 | CHAPMAN, STEVEN LEONARD | Director, CEO AND PRESIDENT | Sale | 296 | $267.08 | $79056.80 |
| 2026-08-03 | CHAPMAN, STEVEN LEONARD | Director, CEO AND PRESIDENT | Sale | 160 | $259.98 | $41596.80 |
| 2026-08-03 | CHAPMAN, STEVEN LEONARD | Director, CEO AND PRESIDENT | Sale | 80 | $265.27 | $21221.60 |
| 2026-08-03 | CHAPMAN, STEVEN LEONARD | Director, CEO AND PRESIDENT | Sale | 70 | $261.03 | $18271.75 |
| 2026-08-03 | BROPHY, MICHAEL BURKES | CHIEF FINANCIAL OFFICER | Sale | 317 | $267.99 | $84952.61 |
| 2026-07-29 | BROPHY, MICHAEL BURKES | CHIEF FINANCIAL OFFICER | Sale | 1,863 | $249.38 | $464594.94 |
| 2026-07-28 | SHEENA, JONATHAN | Director, CO-FOUNDER | Sale | 191 | $254.07 | $48527.29 |
| 2026-07-28 | RABINOWITZ, DANIEL | SEC. AND CHIEF LEGAL OFFICER | Sale | 1,003 | $254.07 | $254832.61 |
| 2026-07-28 | MOSHKEVICH, SOLOMON | PRESIDENT, CLINICALDIAGNOSTICS | Sale | 1,204 | $254.07 | $305900.88 |
| 2026-07-28 | FESKO, JOHN | PRESIDENT, CHIEF BUS. OFFICER | Sale | 931 | $254.07 | $236539.64 |
| 2026-07-28 | CHAPMAN, STEVEN LEONARD | Director, CEO AND PRESIDENT | Sale | 3,580 | $254.07 | $909572.03 |
| 2026-07-28 | BROPHY, MICHAEL BURKES | CHIEF FINANCIAL OFFICER | Sale | 1,241 | $254.07 | $315301.49 |
| 2026-07-28 | BROPHY, MICHAEL BURKES | CHIEF FINANCIAL OFFICER | Sale | 1,008 | $253.77 | $255797.34 |
| 2026-07-28 | BROPHY, MICHAEL BURKES | CHIEF FINANCIAL OFFICER | Sale | 170 | $254.33 | $43236.75 |
| 2026-07-27 | SHEENA, JONATHAN | Director, CO-FOUNDER | Sale | 288 | $260.49 | $75021.35 |
| 2026-07-27 | RABINOWITZ, MATTHEW | Director, EXECUTIVE CHAIRMAN | Sale | 1,718 | $260.49 | $447523.19 |
| 2026-07-27 | RABINOWITZ, DANIEL | SEC. AND CHIEF LEGAL OFFICER | Sale | 884 | $260.49 | $230273.87 |
| 2026-07-27 | MOSHKEVICH, SOLOMON | PRESIDENT, CLINICALDIAGNOSTICS | Sale | 1,010 | $260.49 | $263095.71 |
| 2026-07-27 | FESKO, JOHN | PRESIDENT, CHIEF BUS. OFFICER | Sale | 782 | $260.49 | $203703.81 |
| 2026-07-27 | CHAPMAN, STEVEN LEONARD | Director, CEO AND PRESIDENT | Sale | 2,190 | $260.49 | $570474.85 |
| 2026-07-27 | BROPHY, MICHAEL BURKES | CHIEF FINANCIAL OFFICER | Sale | 782 | $260.49 | $203703.81 |
| 2026-07-15 | SHEENA, JONATHAN | Director, CO-FOUNDER | Sale | 450 | $273.05 | $122871.29 |
| 2026-07-15 | SHEENA, JONATHAN | Director, CO-FOUNDER | Sale | 390 | $273.01 | $106473.43 |
| 2026-07-15 | SHEENA, JONATHAN | Director, CO-FOUNDER | Sale | 180 | $274.99 | $49497.44 |
| 2026-07-15 | SHEENA, JONATHAN | Director, CO-FOUNDER | Sale | 170 | $275.26 | $46794.95 |
| 2026-07-15 | SHEENA, JONATHAN | Director, CO-FOUNDER | Sale | 100 | $273.68 | $27368.40 |
| 2026-07-15 | SHEENA, JONATHAN | Director, CO-FOUNDER | Sale | 90 | $274.26 | $24683.30 |
| 2026-07-15 | SHEENA, JONATHAN | Director, CO-FOUNDER | Sale | 80 | $276.02 | $22081.20 |
| 2026-07-15 | SHEENA, JONATHAN | Director, CO-FOUNDER | Sale | 40 | $276.38 | $11055.20 |
| 2026-07-15 | CHAPMAN, ROWAN E | Director | Sale | 135 | $274.82 | $37100.70 |
| 2026-07-13 | SHEENA, JONATHAN | Director, CO-FOUNDER | Sale | 800 | $264.29 | $211435.52 |
| 2026-07-13 | SHEENA, JONATHAN | Director, CO-FOUNDER | Sale | 500 | $268.39 | $134193.50 |
| 2026-07-13 | SHEENA, JONATHAN | Director, CO-FOUNDER | Sale | 450 | $267.72 | $120474.72 |
| 2026-07-13 | SHEENA, JONATHAN | Director, CO-FOUNDER | Sale | 400 | $265.15 | $106059.52 |
| 2026-07-06 | RABINOWITZ, MATTHEW | Director, EXECUTIVE CHAIRMAN | Sale | 1,000 | $280.00 | $280000.00 |
| 2026-07-01 | RABINOWITZ, DANIEL | SEC. AND CHIEF LEGAL OFFICER | Sale | 3,705 | $268.11 | $993329.77 |
| 2026-07-01 | RABINOWITZ, DANIEL | SEC. AND CHIEF LEGAL OFFICER | Sale | 2,045 | $277.29 | $567055.80 |
| 2026-07-01 | RABINOWITZ, DANIEL | SEC. AND CHIEF LEGAL OFFICER | Sale | 1,955 | $278.25 | $543972.89 |
| 2026-07-01 | RABINOWITZ, DANIEL | SEC. AND CHIEF LEGAL OFFICER | Sale | 1,932 | $268.99 | $519694.09 |
| 2026-07-01 | RABINOWITZ, DANIEL | SEC. AND CHIEF LEGAL OFFICER | Sale | 1,568 | $266.79 | $418330.64 |
| 2026-07-01 | RABINOWITZ, DANIEL | SEC. AND CHIEF LEGAL OFFICER | Sale | 1,400 | $276.24 | $386739.50 |
| 2026-07-01 | RABINOWITZ, DANIEL | SEC. AND CHIEF LEGAL OFFICER | Sale | 1,357 | $270.96 | $367698.83 |
| 2026-07-01 | RABINOWITZ, DANIEL | SEC. AND CHIEF LEGAL OFFICER | Sale | 1,100 | $275.20 | $302716.92 |
| 2026-07-01 | RABINOWITZ, DANIEL | SEC. AND CHIEF LEGAL OFFICER | Sale | 500 | $274.19 | $137095.40 |
| 2026-07-01 | RABINOWITZ, DANIEL | SEC. AND CHIEF LEGAL OFFICER | Sale | 484 | $269.87 | $130615.72 |
| 2026-07-01 | RABINOWITZ, DANIEL | SEC. AND CHIEF LEGAL OFFICER | Sale | 454 | $272.14 | $123551.02 |
| 2026-07-01 | RABINOWITZ, DANIEL | SEC. AND CHIEF LEGAL OFFICER | Sale | 300 | $278.77 | $83630.01 |
| 2026-07-01 | MOSHKEVICH, SOLOMON | PRESIDENT, CLINICALDIAGNOSTICS | Sale | 2,600 | $272.99 | $709774.00 |
| 2026-07-01 | MOSHKEVICH, SOLOMON | PRESIDENT, CLINICALDIAGNOSTICS | Sale | 300 | $274.06 | $82218.00 |
| 2026-07-01 | MOSHKEVICH, SOLOMON | PRESIDENT, CLINICALDIAGNOSTICS | Sale | 100 | $267.19 | $26718.50 |
| 2026-06-26 | RUBIN, ERIC H | Director | Buy | 75 | — | — |
| 2026-06-26 | ROSENMAN, HERM | Director | Buy | 1,571 | — | — |
| 2026-06-26 | ROSENMAN, HERM | Director | Buy | 106 | — | — |
| 2026-06-26 | MARCUS, GAIL BOXER | Director | Buy | 1,571 | — | — |
| 2026-06-26 | MARCUS, GAIL BOXER | Director | Buy | 98 | — | — |
| 2026-06-26 | LYNCH, THOMAS J. JR. | Director | Buy | 1,905 | — | — |
| 2026-06-26 | CHAPMAN, ROWAN E | Director | Buy | 1,571 | — | — |
| 2026-06-26 | CHAPMAN, ROWAN E | Director | Buy | 103 | — | — |
| 2026-06-26 | BOTHA, ROELOF | Director | Buy | 1,571 | — | — |
| 2026-06-26 | BOTHA, ROELOF | Director | Buy | 120 | — | — |
| 2026-06-26 | BERTAGNOLLI, MONICA | Director | Buy | 1,571 | — | — |
| 2026-06-26 | BERTAGNOLLI, MONICA | Director | Buy | 75 | — | — |
| 2026-06-26 | BAYNES, ROY D. | Director | Buy | 1,571 | — | — |
| 2026-06-26 | BAYNES, ROY D. | Director | Buy | 75 | — | — |
| 2026-06-24 | ROSENMAN, HERM | Director | Sale | 16,530 | $250.00 | $4.13M |
| 2026-06-24 | RABINOWITZ, DANIEL | SEC. AND CHIEF LEGAL OFFICER | Sale | 16,204 | $250.25 | $4.06M |
Frequently asked questions
Are NTRA insiders buying or selling?
Over the transactions on record, NTRA insiders have been net sellers, with about $35.93M in stock sold across 85 sales. The entries tagged as buys are stock grants and option exercises recorded at $0, not open-market purchases.
Does insider selling at NTRA mean the stock will fall?
Not by itself. Most executive selling is pre-scheduled through 10b5-1 plans filed months in advance, and insiders sell for diversification, taxes, and liquidity far more often than out of any view on the price. Insider buying is the stronger signal, especially when several insiders buy around the same time, because there is usually only one reason to put personal cash into the stock.
Which NTRA insiders are selling the most?
Recent selling is concentrated in a few names. RABINOWITZ, DANIEL accounts for the largest share on record, with about $9.20M sold. Selling by one or two individuals matters less than broad selling across the whole leadership team, which is the pattern worth watching.